Weiterführende Literatur
Aranake A, Mashour GA, Avidan MS (2013) Minimum alveolar concentration: ongoing relevance and clinical utility. Anaesthesia 68(5):512–22
Blichfeldt-Lauridsen L, Hansen BD (2012) Anesthesia and myasthenia gravis. Acta Anaesthesiol Scand 56(1):17–22
Borghese CM (2015) The molecular pharmacology of volatile anesthetics. Int Anesthesiol Clin 53(2):28–39
Deile M, Damm M, Heller AR (2013) Volatile Anästhetika. Anaesthesist 62(6):493–504
Jakobsson J (2012) Desflurane: a clinical update of a third-generation inhaled anaesthetic. Acta Anaesthesiol Scand 56(4):420–432
Ray DC, Drummond GB (1991) Halothane hepatitis. Br J Anaesth 67(1):84–99
Rosenberg H, Pollock N, Schiemann A et al (2015) Malignant hyperthermia: a review. Orphanet J Rare Dis 4(10):93
Schieren M, Defosse J, Böhmer A et al (2017) Anaesthetic management of patients with myopathies. Eur J Anaesthesiol 34(10):641–649
Stollings LM, Jia LJ, Tang P et al (2016) Immune Modulation by Volatile Anesthetics. Anesthesiology 125(2):399–411
Turner GB, O’Rourke D, Scott GO (2000) Fatal hepatotoxicity after re-exposure to isoflurane: a case report and review of the literature. Eur J Gastroenterol Hepatol 12(8):955–959
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A.R. Heller gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
The supplement containing this article is not sponsored by industry.
Rights and permissions
About this article
Cite this article
Heller, A.R. 83/w nach anästhesiebedingter Hepatitis. Anaesthesist 68 (Suppl 2), 123–126 (2019). https://doi.org/10.1007/s00101-018-0467-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00101-018-0467-9